<div id="readability-page-1"><div><p>Cronos Group (TSX:CRON) opened 2026 with Q1 revenue of US$45.2 million and basic EPS of US$0.04, alongside trailing twelve month revenue of US$159.5 million and a small net loss of US$1.8 million. Over recent quarters the company has seen revenue move from US$30.3 million in Q4 2024 to US$32.3 million in Q1 2025 and US$45.2 million in Q1 2026, while basic EPS has ranged from a loss of US$0.10 in Q2 2025 to a profit of US$0.11 in Q4 2024 and US$0.04 in the latest quarter. This points to a business where margin quality is central to how investors read these results.</p> <p>See our full analysis for Cronos Group.</p><p>With the numbers on the table, the next step is to see how this earnings profile lines up with the most common narratives about Cronos Group and where those stories might need updating.</p> <p>See what the community is saying about Cronos Group</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c2cca9-f26c-48fc-add2-8e319554b2fa/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c2cca9-f26c-48fc-add2-8e319554b2fa/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEz"/><figcaption>TSX:CRON Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>Q1 profit of US$13.8 million contrasts with loss on trailing basis</h2> <ul> <li>Q1 2026 net income excluding extra items was US$13.8 million, while the trailing twelve months still show a small net loss of US$1.8 million, so the latest quarter looks stronger than the recent full year picture.</li> <li>What stands out for the bullish view is that this quarterly profit sits beside forecasts for earnings to grow about 35.2% per year and an expectation of reaching profitability within three years, yet the trailing loss and past quarters like Q2 2025, when the company reported a net loss of US$39.7 million, highlight that the path has been uneven.     <ul> <li>Supporters pointing to Q1 profit can also point to earlier profitable quarters such as Q3 2025 at US$26.0 million and Q4 2024 at US$43.7 million, which line up with the idea that the business can generate earnings in certain periods.</li> <li>At the same time, the trailing twelve month loss of US$1.8 million shows that consistent profitability across a full year has not yet appeared, which keeps the bullish narrative dependent on those forecast growth rates rather than a clean profit track record so far.</li> </ul> </li> </ul> <p>Bulls argue that this mix of recent profitable quarters and earnings growth forecasts could make the company an earlier stage turnaround story, but those trailing losses mean the thesis still rests on execution rather than a fully proven profit history. <strong>🐂 Cronos Group Bull Case</strong></p> <h2>Revenue climbs to US$159.5 million over the last year</h2> <ul> <li>On a trailing twelve month basis, total revenue reached US$159.5 million at Q1 2026, compared with US$117.6 million at Q4 2024, while quarterly revenue moved from US$30.3 million in Q4 2024 to US$45.2 million in Q1 2026.</li> <li>Critics in the bearish narrative focus on how heavily future growth is tied to international markets and cultivation expansion, and the current numbers give them material to work with because revenue is forecast to grow at about 5% per year while the company remains unprofitable on a trailing basis.     <ul> <li>The reliance on expansion projects like GrowCo shows up indirectly in the pattern where quarterly revenue has built from US$32.3 million in Q1 2025 to US$45.2 million in Q1 2026, and bears question whether this trend can hold if regulatory conditions in markets such as Germany or Israel become less favourable.</li> <li>Even with trailing revenue at US$159.5 million, the fact that the trailing period still records a net loss of US$1.8 million supports the cautious view that higher sales alone have not yet translated into firmly positive earnings across a full year.</li> </ul> </li> </ul> <p>Skeptics highlight that while top line growth looks solid in the recent data, the dependence on specific markets and capacity projects keeps the bearish case alive if those drivers do not play out as planned. <strong>🐻 Cronos Group Bear Case</strong></p> <h2>Rich 6.5x P/S multiple versus DCF fair value of US$10.97</h2> <ul> <li>The stock trades at a P/S of 6.5x compared with peer average 1.6x and Canadian Pharmaceuticals industry average 0.9x, while a DCF fair value of about US$10.97 per share sits well above the current share price of US$3.79.</li> <li>Consensus style analysis often flags this kind of split view, where simple multiples look expensive but the cash flow based estimate implies the market price is materially below that DCF fair value, and the tension is clear here because investors are paying a higher sales multiple today while the company is still working toward sustained profitability.     <ul> <li>On one side, the richer P/S ratio versus peers suggests markets are already factoring in the forecast earnings growth of about 35.2% per year and the expectation of profitability within three years, so there is less room for disappointment if the business underperforms those forecasts.</li> <li>On the other side, the gap between US$3.79 and a DCF fair value of US$10.97 signals that, based on the model in the data, the current price embeds much lower long term cash flow than the estimate, so readers need to judge whether the historical volatility in net income, including quarters with losses, justifies that gap.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cronos Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>If the mix of bullish and bearish angles feels finely balanced, it can help to look at the raw data yourself and move quickly to shape your own view, then weigh those points against the 2 key rewards.</p> <h2>See What Else Is Out There</h2> <p>Cronos Group still shows an uneven profit record, a trailing net loss and a rich 6.5x P/S multiple, so expectations leave little room for earnings missteps.</p> <p>If that mix of volatility and premium pricing feels uncomfortable, consider balancing your watchlist with companies screened as 12 resilient stocks with low risk scores and move quickly while conditions still look attractive.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

CRON

<p>Cronos Group (TSX:CRON) reported Q1 2026 revenue of US$45.2 million and a profit of US$13.8 million, contrasting with a trailing twelve-month loss of US$1.8 million. The company has shown revenue growth from US$30.3 million in Q4 2024 to US$45.2 million in Q1 2026, but consistent profitability remains elusive. While bullish investors point to growth forecasts of 35.2% per year, skeptics highlight reliance on international markets and expansion projects, questioning sustainability. The stock trades at a P/S of 6.5x, significantly higher than industry averages, indicating potential market expectations for future earnings growth.</p>

Cronos Group Q1 Profit Of US$13.8 Million Tests Skeptical Earnings Narratives